Revalia Bio

Revalia Bio, Inc. operates a Human Data Trials platform that streamlines drug development processes.Revalia Bio’s primary offering is its Human Data Trials platform, which facilitates drug development by utilizing high-fidelity, organ-based human data obtained from donated, perfused human organs. This innovative approach enables biopharma teams to gain early insights into the safety, efficacy, and mechanisms of action of therapeutic candidates prior to the initiation of clinical trials, addressing significant gaps in traditional drug development methodologies that often rely heavily on animal models. The company targets a variety of stakeholders in the healthcare ecosystem, including physician-scientists, health systems, and biotechnology firms, all of whom benefit from the publication-grade insights generated through Revalia’s platform.Revalia Bio’s revenue model is built on partnerships and collaborations with biopharma companies, health systems, and research institutions, providing them access to its unique Human Data Trials. The transactions typically involve subscription agreements or collaborative research contracts, whereby clients engage Revalia to facilitate studies using human tissues and data. This structure allows clients to leverage Revalia’s infrastructure and expertise to accelerate their own drug discovery processes while sharing in the resultant insights and data. Flagship services include the comprehensive analysis of therapeutic candidates through early human insights that inform trial designs, biomarkers, and dosing strategies.In September 2025, Revalia Bio, Inc. The company aims to enhance its product offerings and explore new markets, particularly in Europe and North America, where its innovative approach to drug development can be effectively integrated.

1. Seed

   Oct 25, 2024

   Amount

   $12M

   Investors

   Locked